Drug-labels.com

Teva-Triacomb: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
1 MG / 100000 UNIT / 2.5 MG / 0.25 MG

Patient Medication Information: uses, side effects, how to take - Teva-Triacomb

WARNINGS AND PRECAUTIONS

General

Patients should be advised to inform subsequent physicians of the prior use of corticosteroids.

TEVA-TRIACOMB should not be used under occlusive dressings (see ADVERSE REACTIONS).

Cardiovascular

Topical corticosteroids should be used with caution in patients with stasis dermatitis and other skin diseases associated with impaired circulation. If a symptomatic response is not noted within 7 days, the patient should be re-evaluated. Prolonged use of topical antibiotics should be avoided.

Endocrine and Metabolism

Although adrenal suppression and other systemic adverse effects are rare with topical corticosteroid preparations, their possible occurrence must be kept in mind, particularly when these preparations are used over large areas or for an extended period of time. Prolonged use may lead to steroid withdrawal when the medication is discontinued.

Because of the potential hazard of nephrotoxicity and ototoxicity, avoid prolonged use or the use of large amounts in the treatment of skin infections following burns, tropic ulceration and other conditions when absorption of neomycin is possible.

Gramicidin absorption following topical administration is unlikely; however, hemolysis may occur should the drug enter the blood. If gramicidin is allowed in close proximity to the sub-arachnoid space, a chemical arachnoiditis may occur (see ADVERSE REACTIONS).

Ophthalmologic

Topical corticosteroids should be used with caution on lesions close to the eye. Posterior subcapsular cataracts have been observed following systemic corticosteroid therapy (see ADVERSE REACTIONS).

Sensitivity

Hypensitivity of nystatin is extremely uncommon. Sensitivity reactions following the topical use of gramicidin or triamcinolone acetonide are rarely encountered. Burning, itching, irritation, dryness, erythema, folliculitis, hypertrichosis, acnelform eruptions, tinnitus, deafness and hypopigmentation have been reported with topical corticosteroids.

An increase in the incidence of patients allergic to neomycin has been reported in literature.

Neomycin itself may cause an allergic otitis extema. Systemic neomycin toxicity has occurred rarely following topical administration; tinnitus and deafness have been reported (see ADVERSE REACTIONS).

Susceptibility/Resistance

Development of Drug Resistant Bacteria: Prescribing TEVA-TRIACOMB in the absence of the authorized indications is unlikely to provide benefit to the patient and risks the development of resistant organisms.

Potential for Microbial Overgrowth: As with any antibiotic preparation, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi other than candida. Constant observation of the patient is essential. Should superinfection due to non-susceptible organisms occur, TEVA-TRIACOMB should be discontinued and appropriate therapy instituted.

Skin

When steroid preparations are used for long periods in intertriginous areas or under occlusive dressings, striae may occur. Damage to collagen, which constitutes a middle layer of the tympanic membrane, may occur. Delayed healing and systemic effects, including adrenal suppression and subcapsular cataracts, may occur if absorbed in appreciable amounts.

If local irritation or sensitization develops, TEVA-TRIACOMB should be discontinued and appropriate therapy instituted. Prolonged use of corticosteroids may produce atrophy of the skin and subcutaneous tissues, particularly on flexor surfaces and on the face. If this is noted, discontinue the use of the product.

The use of occlusive dressings is not recommended with products containing anti-infective agents (see ADVERSE REACTIONS).

Special Populations

Pregnant Women: The safety of Topical Corticosteroid preparations during pregnancy and lactation has not been established. The potential benefit of the use of topical corticosteroids during pregnancy should be weighed against possible hazards to the fetus.

Nursing Women: It is not known whether Topical Corticosteroids are excreted in human milk.

Topical Corticosteroids should not be used during breast feeding unless the potential benefit justifies the potential risk to the nursing infant.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

The following adverse skin reactions have been reported with the use of topical corticosteroids: dryness, itching, burning, local irritation, skin atrophy, striae, atrophy of subcutaneous tissue, folliculitis, acneiform eruptions, hypertrichosis, change in skin pigmentation and telangiectasia.

Adrenal suppression has also been reported following topical corticosteroid therapy. Posterior subcapsular cataracts have been observed following systemic corticosteroid therapy.

Hypersensitivity reactions to neomycin, gramicidin, and nystatin have been reported. Systemic neomycin toxicity has occurred rarely following topical administration; tinnitus and deafness have also been reported. Overgrowth of non-susceptible organisms has occurred.

DOSAGE AND ADMINISTRATION

Each gram of TEVA-TRIACOMB contains triamcinolone acetonide 1 mg, nystatin 100,000 units, neomycin base (as sulfate) 2.5 mg and gramicidin 0.25 mg.

Apply a small quantity two or three times daily. Do not apply more than prescribed by physician. For external use only.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

Percutaneous absorption of corticosteroids can occur, especially if used over a large area for prolonged periods of time. If large amounts of corticosteroids are absorbed, toxic effects may include mild reversible suppression of adrenal function, ecchymoses of the skin, peptic ulceration, hypertension, aggravation of infections, hirsutism, acne, edema and muscle weakness due to protein depletion. Prolonged use of large amounts of TEVA-TRIACOMB would likely increase the absorption of neomycin which in turn would enhance the potential for nephrotoxicitiy and ototoxicity as well as ulceration.

No specific antidote is available, treatment should be primarily symptomatic and administration of the cream discontinued.

ACTION AND CLINICAL PHARMACOLOGY

TEVA-TRIACOMB provides relief from the itching and burning associated with secondarily infected inflammatory conditions by virtue of:

  • the anti-inflammatory antipruritic and vasoconstrictive properties of triamcinolone

    acetonide;

  • the broad spectrum anti-bacterial activity of neomycin and gramicidin;
  • the anti-candidal activity of nystatin.

STORAGE AND STABILITY

Store at room temperature, 15 °C – 30 °C. Keep tube tightly closed. Do not freeze.

DOSAGE FORMS, COMPOSITION AND PACKAGING

TEVA-TRIACOMB is a yellow, homogeneouscream. Absence of

foreign matter.

TEVA-TRIACOMB: Each gram contains 1 mg triamcinolone acetonide, 100,000 units nystatin, 2.5 mg neomycin (as sulphate), 0.25 mg gramicidin, aluminum hydroxide, ceteareth-20, cetearyl alcohol, glyceryl monostearate, glyceryl stearate, methylparaben, petrolatum, polysorbate 60, propylene glycol, propylene glycol monostearate, propylparaben, purified water, sorbitol and titanium dioxide.

TEVA-TRIACOMB is available in 15, 30 and 60 g tubes and in 450 g jars.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substances

Proper name: Triamcinolone acetonide

Chemical name: 9-Fluoro-11, 21-dihydroxy-16, 17-[1 - methylethylidenebis(oxy)] pregna - 1, 4 - diene - 3, 20 - dione; 9 α - fluoro - 11ß, 16 α, 17, 21 - tetrahydroxypregna - 1, 4 - diene - 3, 20 - dione cyclic 16, 17 - acetal with acetone

Molecular formula and molecular mass: C24 H31 FO6, 434.49 g/mol

Structural formula:

O CH3 CO CH 2OH . . . . . . O O 3 CH3 HO F C (CH )2

Physicochemical properties:

Description: White to cream-colored, with a light odor crystalline powder.

Solubility: Practically insoluble in water, very soluble in dehydrated alcohol, chloroform and methyl alcohol.

Proper name: Neomycin

Chemical name: O - 2, 6 - diamino - 2, 6 - dideoxy - α - D - glucopyranosyl - (1→3) - O - ß - D - ribofuranosyl - (1→5) - O - [2, 6 - diamino - 2, 6 - dideoxy -α - D - glucopyranosyl - (1→4)] - 2 - deoxy - D - streptamine for neomycin B, replace α - D - glucopyranosyl by ß - L – idopyranosyl

Molecular formula and molecular mass: C23 H46 N6 O13, 614.7 g/mol

Structural formula:

Physicochemical properties:

Description: Neomycin base (in sulfate): white or yellowish-white, odorless or almost odorless, hydroscopic powder.

Solubility: Neomycin base (in sulfate): Soluble 1 in 1 of water; very slightly soluble in alcohol; practically insoluble in acetone, chloroform and ether.

Proper name: Gramicidin

Chemical name: Gramicidin

Molecular formula and molecular mass: 1. gramicidin J1

C44 H65 N9 O7, 831 g/mol

  1. 2. gramicidin T2

C35 H56 N8 O6, 684 g/mol

  1. 3. gramicidin S

C60 H92 N12 O10, 1140 g/mol

Structural formula:

  1. 1. gramicidin J1

L-Phe-D-Leu-D-Phe-L-Orn-L-Val-b-Orn-L-Pro

  1. 2. gramicidin T2

b-Phe-D-Leu-L-Orn-L-Val-D-Orn-L-Pro

  1. 3. gramicidin S

L-Val-L-Orn-L-Leu-D-Phe-L-Pro L-Pro-D-Phe-L-Leu-L-Orn-L-Val

Physicochemical properties:

Description: White or almost white, odorless, crystalline powder.

Solubility: Soluble in alcohol, acetic acid, pyridine; moderately soluble in dry acetone and dioxane. Practically insoluble in ether, hydrocarbons.

Proper name: Nystatin

Chemical name: Nystatin

Molecular Formula C47 H75 NO17, 926.1 g/mol

Structural formula:

OH H O HO NH C 2 3H OH OH OH OH OH OH OH HO O CH H C CH O 3 3 3 O COOH O

Physicochemical properties:

Description: Yellow to light tan powder, having an odor suggestive of cereals. It is hydroscopic and is affected by long exposure to light, heat and air.

Solubility: Very slightly soluble in water, slightly to sparingly soluble in alcohol, methyl alcohol, n-propyl alcohol and n-butyl alcohol; insoluble in chloroform and ether.

REFERENCES

  1. 1.

    PrVIADERM K.C.® CREAM and PrVIADERM K.C.® OINTMENT (Triamcinolone Acetonide 1 mg/g, Nystatin 100,000 units/g, Neomycin base (as sulphate) 2.5 mg/g, and Gramicidin 0.25 mg/g) Product Monograph, Taro Pharmaceuticals Inc Date of Revision: July 5, 2018. Control Number: 214456.

    READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

    PATIENT MEDICATION INFORMATION

    PrTEVA-TRIACOMB

    Triamcinolone Acetonide, Nystatin, Neomycin Sulfate,

    and Gramicidin Cream

    USP

Read this carefully before you start taking TEVA-TRIACOMB and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about TEVA-TRIACOMB.

What is TEVA-TRIACOMB used for?

TEVA-TRIACOMB (Triamcinolone Acetonide, Nystatin, Neomycin Sulfate, and Gramicidin) is used to provide relief from the itching, burning, and swelling caused by bacterial and/or fungal infections.

TEVA-TRIACOMB contain antibacterial ingredients called gramicidin and neomycin, and should be used exactly as directed by your health care professional.

How does TEVA-TRIACOMB work?

TEVA-TRIACOMB is antibacterial and antifungal which destroy the bacteria and fungi (yeasts) causing the skin infections.

How to take TEVA-TRIACOMB?

Misuse or overuse of TEVA-TRIACOMB could lead to the growth of bacteria that will not be killed by gramicidin and/or neomycin (resistance). This means that TEVA-TRIACOMB or other medicines that contain gramicidin and/or neomycin may not work for you in the future.

Do not share your medicine.

What are the ingredients in TEVA-TRIACOMB?

Medicinal ingredients: Triamcinolone Acetonide, Nystatin, Neomycin Sulfate, and Gramicidin Non-medicinal ingredients: aluminum hydroxide, ceteareth-20, cetearyl alcohol, glyceryl monostearate, glyceryl stearate, methylparaben, petrolatum, polysorbate 60, propylene glycol, propylene glycol monostearate, propylparaben, purified water, sorbitol and titanium dioxide

TEVA-TRIACOMB comes in the following dosage forms:

TEVA-TRIACOMB (Triamcinolone Acetonide 1 mg / g, Nystatin 100,000 units / g, Neomycin base (as sulphate) 2.5 mg / g, and Gramicidin 0.25 mg / g) is available in 15 g, 30 g, and 60 g tubes, and in 450 g jars.

Do not use TEVA-TRIACOMB:

  • if you are allergic to Triamcinolone Acetonide, Nystatin, Neomycin Sulfate, and Gramicidin or any of its non-medicinal ingredients (See What are the ingredients of TEVA-TRIACOMB),
  • if you have primary skin infections,
  • if you have any serious skin lesions, most viral lesions of the skin (including chicken pox (varicella) cold sores or genital herpes (Herpes simplex)), and fungal skin lesions except caused by yeasts infections,
  • in your eyes,
  • in the outer area of your ear if you have an ear infection or holes in your eardrums (see p. 4), and
  • under covered skin dressing if you have skin swelling and infections

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take TEVA-TRIACOMB. Talk about any health conditions or problems you may have, including:

  • your previous use of corticosteroids,
  • if your condition has not changed within 7 days,
  • if you use it for large skin areas,
  • if you have skin lesions close to the eye, and
  • if you have allergic reactions such as burning, itching, irritation, dryness, and skin discoloration.

Other warnings you should know about:

  • Avoid contact with the eyes. If accidental contact occurs, rinse the eyes thoroughly with water
  • If further skin irritation develops or the infection worsens, contact your doctor.
  • Avoid continuous or prolonged use as potential adverse effects increase with longer use.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with TEVA-TRIACOMB:

Drug interactions studies have not been done for TEVA-TRIACOMB.

How to take TEVA-TRIACOMB:

Small quantity 2 or 3 times daily.

Usual dose:

Apply a small amount to the affected area 2 or 3 times daily.

Do not apply to open wounds or burns to avoid absorption of the drug(s) into the blood. Do not apply more than prescribed by the doctor. For external use only.

Overdose:

If you think you have applied too much TEVA-TRIACOMB, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

What are possible side effects from using TEVA-TRIACOMB?

  • Skin reactions such as burning, itching, irritation, dryness, and skin discoloration.

These are not all the possible side effects you may feel when taking TEVA-TRIACOMB. If you experience any side effects not listed here, contact your healthcare professional. Please also see Warnings and Precautions.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or

Calling toll-free at 1-866-234-2345

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store at room temperature between 15ºC and 30ºC. Keep tube tightly closed. Do not freeze. Keep out of reach and sight of children.

If you want more information about TEVA-TRIACOMB:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (https://health-products.canada.ca/dpd-bdpp/index-eng.jsp); the manufacturer’s website http://www.tevacanada.com; or by calling 1-800-268-4127 ext. 3; or email druginfo@tevacanada.com.

Last Revised: January 17, 2019

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 00550507

Revision date stated in the text: January 17, 2019

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Teva-Triacomb

Rx or OTC
Prescription (Rx)?
DIN 00550507
Schedule(s) PRESCRIPTION
Active ingredient(s) Triamcinolone acetonide 1 MG, Nystatin 100000 UNIT, Neomycin (neomycin sulfate) 2.5 MG, Gramicidin 0.25 MG
Dosage form(s) Cream
Route(s) of administration Topical
Drug class (WHO ATC)
  1. D Dermatologicals
    1. D07 Corticosteroids, dermatological preparations
      1. D07C Corticosteroids, combinations with antibiotics
        1. D07CB Corticosteroids, moderately potent, combinations with antibiotics
          1. D07CB01 Triamcinolone and antibiotics
Company TEVA CANADA LIMITED
Current status Marketed
Current status date January 10, 2018

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.